Literature DB >> 453213

Assuring the quality of intravenous admixture programs.

M H Stolar.   

Abstract

Several aspects of quality assurance (QA) methods in i.v. admixture programs are discussed, and a basic framework for developing QA programs for admixture services is presented. The objective of QA is to insure that admixture products: (1) are therapeutically and pharmaceutically appropriate to the patient; (2) are free from microbial and pyrogenic contaminants; (3) are free from undesirable levels of particulate or toxic contaminants; (4) contain drugs in correct amounts; and (5) are labeled, stored and distributed under principles of good drug control. Three types of QA criteria bases which may be used as indicators of quality are discussed (resources, facilities and organization; required procedures; end-products or results). Because end-product monitoring has certain limitations in the admixture setting, QA must rely heavily on procedure-centered review methods. General guidelines for developing QA programs are outlined. Adherence to procedure is the key to assuring the quality of admixture products. In developing a QA program, the highest priority should be given to the education and training of admixture personnel, particularly with respect to aseptic technique and pharmaceutical calculations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 453213

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  2 in total

1.  Microbiological aspects of heat sterilization of drugs. III. Heat resistance of spore-forming bacteria, isolated from large-volume parenterals.

Authors:  F A Boom; M A Van der Heijden Van Beek; A C Paalman; A Stout-Zonneveld
Journal:  Pharm Weekbl Sci       Date:  1991-06-21

2.  Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting.

Authors:  Phillipe van der Linden; Jacques Douchamps; Claude Schmitt; Dominique Forget
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.